Business Context and Reporting Period
Company: InspireMD, Inc. (NSPR)
Filing Type: Form 8-K (Current Report)
Date of Report: June 23, 2025
Reporting Period: Event-based report regarding regulatory approval received on June 23, 2025, and press release issued June 24, 2025.
Key Financial Metrics
This filing is a Current Report on Form 8-K and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The primary material change reported is the receipt of U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) for the Company's CGuard Prime Carotid Stent System. This approval was received on June 23, 2025, following a PMA application submitted on September 16, 2024.
Guidance, Outlook, and Management Commentary
- Regulatory Milestone: The Company announced FDA PMA approval for the CGuard Prime Carotid Stent System, intended for the prevention of stroke.
- Investor Communications: On June 24, 2025, the Company issued a press release (Exhibit 99.1) and an updated investor presentation (Exhibit 99.2).
- Legal Disclaimer: Information furnished under Item 7.01, including the press release and presentation, is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Investor Verification Checklist
- Verify the commercial launch timeline for the CGuard Prime Carotid Stent System following FDA approval.
- Review the full text of the June 24, 2025 press release (Exhibit 99.1) for specific indications and limitations of the approval.
- Examine the updated investor presentation (Exhibit 99.2) for revised financial projections or market strategy.
- Confirm the status of the Company's cash position and funding requirements to support commercialization, as this 8-K does not disclose current liquidity.